490 related articles for article (PubMed ID: 15960560)
21. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat.
Cookson J; Gilaberte I; Desaiah D; Kajdasz DK
Int Clin Psychopharmacol; 2006 Sep; 21(5):267-73. PubMed ID: 16877897
[TBL] [Abstract][Full Text] [Related]
22. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS
J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026
[TBL] [Abstract][Full Text] [Related]
23. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine.
Hirschfeld RM; Vornik LA
J Clin Psychiatry; 2004; 65 Suppl 4():46-52. PubMed ID: 15046541
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder.
Brecht S; Kajdasz D; Ball S; Thase ME
Int Clin Psychopharmacol; 2008 Nov; 23(6):317-24. PubMed ID: 18854719
[TBL] [Abstract][Full Text] [Related]
25. Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.
Oakes TM; Katona C; Liu P; Robinson M; Raskin J; Greist JH
Int Clin Psychopharmacol; 2013 Jan; 28(1):1-11. PubMed ID: 23138680
[TBL] [Abstract][Full Text] [Related]
26. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients.
Lewis-Fernández R; Blanco C; Mallinckrodt CH; Wohlreich MM; Watkin JG; Plewes JM
J Clin Psychiatry; 2006 Sep; 67(9):1379-90. PubMed ID: 17017824
[TBL] [Abstract][Full Text] [Related]
27. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
28. Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study.
Dueñas H; Lee A; Brnabic AJ; Chung KF; Lai CH; Badr MG; Uy-Ponio T; Ruiz JR; Varrey P; Jian H; Dossenbach M
Int J Psychiatry Clin Pract; 2011 Jun; 15(2):80-90. PubMed ID: 22121855
[TBL] [Abstract][Full Text] [Related]
29. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.
Goldstein DJ; Lu Y; Detke MJ; Wiltse C; Mallinckrodt C; Demitrack MA
J Clin Psychopharmacol; 2004 Aug; 24(4):389-99. PubMed ID: 15232330
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo.
Clayton AH; Reddy S; Focht K; Musgnung J; Fayyad R
J Sex Med; 2013 Mar; 10(3):768-76. PubMed ID: 22905811
[TBL] [Abstract][Full Text] [Related]
31. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
[TBL] [Abstract][Full Text] [Related]
32. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses.
Gueorguieva R; Mallinckrodt C; Krystal JH
Arch Gen Psychiatry; 2011 Dec; 68(12):1227-37. PubMed ID: 22147842
[TBL] [Abstract][Full Text] [Related]
33. Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial.
Perahia DG; Maina G; Thase ME; Spann ME; Wang F; Walker DJ; Detke MJ
J Clin Psychiatry; 2009 May; 70(5):706-16. PubMed ID: 19552867
[TBL] [Abstract][Full Text] [Related]
34. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
35. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors.
Landén M; Eriksson E; Agren H; Fahlén T
J Clin Psychopharmacol; 1999 Jun; 19(3):268-71. PubMed ID: 10350034
[TBL] [Abstract][Full Text] [Related]
36. Relationship between TSH levels in the normal range and short-term duloxetine efficacy.
Corruble E; Goldberger C; Spann M
J Affect Disord; 2010 Jun; 123(1-3):312-6. PubMed ID: 19825504
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
Raskin J; Wiltse CG; Siegal A; Sheikh J; Xu J; Dinkel JJ; Rotz BT; Mohs RC
Am J Psychiatry; 2007 Jun; 164(6):900-9. PubMed ID: 17541049
[TBL] [Abstract][Full Text] [Related]
38. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
39. Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial.
Jacobsen P; Zhong W; Nomikos G; Clayton A
J Sex Med; 2019 Oct; 16(10):1638-1649. PubMed ID: 31405765
[TBL] [Abstract][Full Text] [Related]
40. Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period.
Dueñas H; Brnabic AJ; Lee A; Montejo AL; Prakash S; Casimiro-Querubin ML; Khaled M; Dossenbach M; Raskin J
Int J Psychiatry Clin Pract; 2011 Nov; 15(4):242-54. PubMed ID: 22121997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
